Clinical trials: Liraglutide
Type 1 Diabetes Mellitus
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
Each subject will be allocated to 2 periods of 3 months of once daily dosing with either liraglutide (1.2 mg) or placebo treatment (in random sequence) as add on to usual intensive insulin treatment.
- Trial name
- NCT02408705
- Testing
- Liraglutide, Mixed Meal Tolerance Test with paracetamol
- Where
- Austria
- Volunteers
- 14 people
- Sponsor
- Medical University of Graz
Obesity (BMI Equal to or >30), Weight Regain After Bariatric Surgery
Changes in Body Composition Following Pharmacological Treatment for Obesity.
Background: Intentional weight loss via various treatments results in a loss of lean mass of approximately 10% for every 10 kg of total weight lost.
- Trial name
- NCT07908940
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Hospital San Carlos, Madrid
Diabetes Mellitus, Type 2
Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type…
- Trial name
- NCT01790308
- Testing
- CSII, Liraglutide
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Diabetes, Diabetes Mellitus, Type 2
The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Europe and North America. The aim of this trial is to compare the effect on blood sugar control of liraglutide or sitagliptin, both in combination with metformin, in subjects with type 2 diabetes…
- Trial name
- NCT00700817
- Testing
- liraglutide, sitagliptin, metformin
- Where
- 166 sites in United States, Canada and 13 more
- Volunteers
- 665 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
This study is being done to compare the effectiveness and safety of two treatment paradigms (oral sitagliptin with or without glimepiride versus liraglutide with or without increased dosing) for the treatment of participants with…
- Trial name
- NCT01296412
- Testing
- sitagliptin, liraglutide, glimepiride
- Volunteers
- 653 people
- Sponsor
- Merck Sharp & Dohme LLC
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Obesity
Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities
We performed a multicenter, randomized, double-blind, placebo-controlled 28-week trial. 300 non-diabetic obese subjects or overweight subjects with co-morbidities were randomly assigned.
- Trial name
- NCT04525300
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xiangya Hospital of Central South University
Diabetes, Diabetes Mellitus, Type 2
Safety of Liraglutide in Pediatric Patients With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered…
- Trial name
- NCT00943501
- Testing
- liraglutide
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY®…
- Trial name
- NCT06559722
- Testing
- Insulin Degludec/liraglutide Injection, XULTOPHY®
- Volunteers
- 510 people
- Sponsor
- Tonghua Dongbao Pharmaceutical Co.,Ltd
Obesity & Overweight
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that…
- Trial name
- GLP-BARI-VAN (NCT07901777)
- Testing
- GLP-1 Receptor Agonist Therapy, Laparoscopic Sleeve Gastrectomy
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Yuzuncu Yil University
Obesity in Children, Bone Strength
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 receptor agonists (GLP-1RAs) as compared to those…
- Conditions
- Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification
- Trial name
- NCT06903923
- Testing
- GLP-1 receptor agonist, Lifestyle intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Virginia
Diabetes
DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists
The purpose of this study is to collect a cohort of patients treated with GLP-1R Agonists and to assess phenotypic, genetic and genomic biomarkers of glycaemic response to these agents.
- Trial name
- DIRECTGLP (NCT01575301)
- Testing
- Exenatide, Liraglutide
- Where
- 4 sites in United Kingdom
- Volunteers
- 411 people
- Sponsor
- University of Dundee
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
- Trial name
- DUAL™ V (NCT01952145)
- Testing
- insulin degludec/liraglutide, insulin glargine
- Where
- 91 sites in United States, Argentina and 8 more
- Volunteers
- 557 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
A phase 2 study in two parts (A \& B) designed to evaluate the effect of MEDI0382 on Hepatic Glycogen Metabolism in subjects with Type 2 Diabetes Mellitus (T2DM).
- Trial name
- NCT03555994
- Testing
- MEDI0382, Liraglutide
- Where
- 3 sites in Netherlands, Sweden and 1 more
- Volunteers
- 51 people
- Sponsor
- MedImmune LLC
Alzheimer's Disease
Evaluating Liraglutide in Alzheimer's Disease
This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.
- Trial name
- ELAD (NCT01843075)
- Testing
- Liraglutide
- Where
- United Kingdom
- Volunteers
- 204 people
- Sponsor
- Imperial College London
Type 2 Diabetic Patients
A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus
A randomized open, positive parallel controlled clinical study design was adopted. Participants were randomly assigned 1:1 according to inclusion criteria and exclusion criteria into two treatment regiments: Delu insulin…
- Trial name
- TLI vs PMI (NCT06925334)
- Testing
- Degludec insulin
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Diabetes, Healthy
Safety and Tolerability of NN9068 in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068.
- Trial name
- NCT00983021
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
- Trial name
- NCT03856047
- Testing
- NNC0174-0833, Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Knee Osteoarthritis
Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee
This phase I study is a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and tolerability of single ascending dose of IA 4P-004 in participants, Between 18 and 80 years of age, with target knee…
- Trial name
- LASARE (NCT05419856)
- Testing
- 4P-004
- Where
- 3 sites in Belgium
- Volunteers
- 34 people
- Sponsor
- 4Moving Biotech
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed by HbA1c after 24 weeks and 52…
- Trial name
- NCT00395746
- Testing
- sulfonylurea, liraglutide
- Where
- Japan
- Volunteers
- 264 people
- Sponsor
- Novo Nordisk A/S